Please login to the form below

Not currently logged in
Email:
Password:

bezlotoxumab

This page shows the latest bezlotoxumab news and features for those working in and with pharma, biotech and healthcare.

Microbiome specialist Rebiotix chalks up C. diff trial success

Microbiome specialist Rebiotix chalks up C. diff trial success

Meanwhile, other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck &Co's recently-approved Zinplava (bezlotoxumab) - which works by neutralising toxins secreted by the bacterium - and

Latest news

  • After delay, Merck gets US approval for serious infection drug After delay, Merck gets US approval for serious infection drug

    2020. A marketing authorisation application for bezlotoxumab has been filed with the EMA and is also under review. ... Bezlotoxumab was originally developed by Medarex, which was acquired by Bristol-Myers Squibb in 2009.

  • Merck prepares filings for Clostridium antibody Merck prepares filings for Clostridium antibody

    Another antibody being developed as a combination with bezlotoxumab, actoxumab, was dropped from the study for "efficacy and safety reasons" after an interim analysis, according to Merck. ... Bezlotoxumab and actoxumab were developed in house by Merck in

  • UPDATE: Merck to acquire Cubist for $8.4bn UPDATE: Merck to acquire Cubist for $8.4bn

    Actoxumab/bezlotoxumab (MK-3415A) is a combination of two antibodies in phase III development to prevent recurrence of the serious infection Clostridium difficile.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics